[New therapies for type 2 diabetes mellitus]

Med Clin (Barc). 2015 Jun 22;144(12):560-5. doi: 10.1016/j.medcli.2014.03.018. Epub 2014 Sep 4.
[Article in Spanish]

Abstract

The increasing prevalence of obesity and type 2 diabetes mellitus (T2DM) has led to a growing interest in the investigation of new therapies. Treatment of T2DM has focused on the insulinopenia and insulin resistance. However, in the last 10 years, new lines of research have emerged for the treatment of T2DM and preclinical studies appear promising. The possibility of using these drugs in combination with other currently available drugs will enhance the antidiabetic effect and promote weight loss with fewer side effects. The data provided by post-marketing monitoring will help us to better understand their safety profile and potential long-term effects on target organs, especially the cardiovascular risk.

Keywords: Diabetes tipo 2; Future; Futuro; Tratamiento; Treatment; Type 2 diabetes mellitus.

Publication types

  • English Abstract
  • Review

MeSH terms

  • 11-beta-Hydroxysteroid Dehydrogenase Type 1 / antagonists & inhibitors
  • Anti-Obesity Agents / adverse effects
  • Anti-Obesity Agents / therapeutic use
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diacylglycerol O-Acyltransferase / antagonists & inhibitors
  • Dipeptidyl Peptidase 4 / drug effects
  • Drug Therapy, Combination
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / therapeutic use
  • Enzyme Inhibitors / therapeutic use
  • Glucagon / agonists
  • Glucagon-Like Peptide-1 Receptor / agonists
  • Glucokinase / drug effects
  • Gluconeogenesis / drug effects
  • Glucose / pharmacokinetics
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / classification
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Incretins
  • Insulin Resistance
  • Insulin, Long-Acting / therapeutic use
  • Molecular Targeted Therapy*
  • Obesity / complications
  • Obesity / drug therapy
  • Phosphofructokinase-2 / antagonists & inhibitors
  • Sodium-Glucose Transport Proteins / antagonists & inhibitors
  • Weight Loss

Substances

  • Anti-Obesity Agents
  • Drugs, Investigational
  • Enzyme Inhibitors
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Incretins
  • Insulin, Long-Acting
  • Sodium-Glucose Transport Proteins
  • Glucagon
  • 11-beta-Hydroxysteroid Dehydrogenase Type 1
  • HSD11B1 protein, human
  • Diacylglycerol O-Acyltransferase
  • Phosphofructokinase-2
  • Glucokinase
  • DPP4 protein, human
  • Dipeptidyl Peptidase 4
  • Glucose